KR20140135813A - 다제 내성 박테리아의 억제 또는 치료를 위한 풀브산과 항생제 조합 - Google Patents

다제 내성 박테리아의 억제 또는 치료를 위한 풀브산과 항생제 조합 Download PDF

Info

Publication number
KR20140135813A
KR20140135813A KR1020147028255A KR20147028255A KR20140135813A KR 20140135813 A KR20140135813 A KR 20140135813A KR 1020147028255 A KR1020147028255 A KR 1020147028255A KR 20147028255 A KR20147028255 A KR 20147028255A KR 20140135813 A KR20140135813 A KR 20140135813A
Authority
KR
South Korea
Prior art keywords
fulvic acid
salt
multidrug
resistant
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020147028255A
Other languages
English (en)
Korean (ko)
Inventor
스티픈 윌리엄 레이버스
피터 완
Original Assignee
나트라신 유케이 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 나트라신 유케이 리미티드 filed Critical 나트라신 유케이 리미티드
Publication of KR20140135813A publication Critical patent/KR20140135813A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020147028255A 2012-03-07 2013-03-06 다제 내성 박테리아의 억제 또는 치료를 위한 풀브산과 항생제 조합 Ceased KR20140135813A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ZA2012/01683 2012-03-07
ZA201201683 2012-03-07
PCT/IB2013/051772 WO2013132444A1 (en) 2012-03-07 2013-03-06 Fulvic acid and antibiotic combination for the inhibition or treatment of multi-drug resistant bacteria

Publications (1)

Publication Number Publication Date
KR20140135813A true KR20140135813A (ko) 2014-11-26

Family

ID=48142838

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147028255A Ceased KR20140135813A (ko) 2012-03-07 2013-03-06 다제 내성 박테리아의 억제 또는 치료를 위한 풀브산과 항생제 조합

Country Status (8)

Country Link
US (1) US9265744B2 (enExample)
EP (1) EP2822551B1 (enExample)
KR (1) KR20140135813A (enExample)
CN (1) CN104203227A (enExample)
IN (1) IN2014DN07194A (enExample)
MY (1) MY170829A (enExample)
RU (1) RU2640928C2 (enExample)
WO (1) WO2013132444A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10201518B2 (en) 2016-09-28 2019-02-12 The University Of Hong Kong Bismuth(III) compounds and methods thereof
CN109706195B (zh) * 2018-12-27 2022-04-08 齐齐哈尔龙江阜丰生物科技有限公司 颗粒型苏氨酸的生产工艺
CN111616358A (zh) * 2020-06-20 2020-09-04 田劭军 一种用于提高免疫力的组合物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ225271A (en) 1987-07-08 1991-02-26 Nat Energy Council Oxidising coal using a gaseous oxidant
DE3903773A1 (de) 1988-02-11 1989-09-14 Nat Energy Council Eine mischung mit bakteriozider oder bakteriostatischer aktivitaet
US5204368A (en) 1990-05-25 1993-04-20 National Energy Council Bacteriostatic and bacteriocidal method using fulvic acid derivatives
EP1700599B1 (en) 1998-10-08 2008-10-08 Pfeinsmith Limited Fulvic acid and its use in the treatment of candida infections
ES2360232T3 (es) 2005-06-29 2011-06-02 Compumedics Limited Conjunto sensor con puente conductor.
BRPI0709711A2 (pt) * 2006-05-02 2011-07-26 Pfeinsmith S A Pty Ltd composiÇço, e, mÉtodo de fabricar a mesma.
CN102099027B (zh) * 2008-06-05 2012-12-12 皮费恩史密斯有限公司 富里酸及抗生素组合物

Also Published As

Publication number Publication date
WO2013132444A1 (en) 2013-09-12
EP2822551B1 (en) 2016-12-21
US9265744B2 (en) 2016-02-23
MY170829A (en) 2019-09-05
CN104203227A (zh) 2014-12-10
EP2822551A1 (en) 2015-01-14
RU2014140227A (ru) 2016-04-27
US20150031767A1 (en) 2015-01-29
RU2640928C2 (ru) 2018-01-12
IN2014DN07194A (enExample) 2015-04-24

Similar Documents

Publication Publication Date Title
Tré-Hardy et al. In vitro activity of antibiotic combinations against Pseudomonas aeruginosa biofilm and planktonic cultures
Lebeaux et al. Biofilm-related infections: bridging the gap between clinical management and fundamental aspects of recalcitrance toward antibiotics
US20060228384A1 (en) Control of biofilm with a biofilm inhibitor
US20250170106A1 (en) Use of su3327 in preparation of medicament for enhancing efficacy of polymyxin against bacterial infection
CN103826639A (zh) 包含头孢菌素和β-内酰胺酶抑制剂的组合的抗生素
KR20140135813A (ko) 다제 내성 박테리아의 억제 또는 치료를 위한 풀브산과 항생제 조합
Soundhararajan et al. Polyherbal nano formulation: A potent antibiotic resistance breaker in bovine mastitis causing MDR pathogens
CN102099027B (zh) 富里酸及抗生素组合物
US20130337095A1 (en) Antimicrobial composition and its method of use
WO2004022048A1 (en) Fosfomycin and n-acetylcysteine for the treatment of biofilms caused by escheric ia coli and other pathogens of the urinary tract
US20250099495A1 (en) Methods of inhibiting klebsiella pneumoniae carbapenemase-2
Helaly et al. Dexpanthenol and propolis extract in combination with local antibiotics for treatment of Staphylococcal and Pseudomonal wound infections.
CN112438989B (zh) 一种非抗生素类抗菌组合物及其应用
KR101404149B1 (ko) 온천수를 포함하는 세균성 전립선염의 예방 및 치료용 조성물
CN101816669B (zh) 一种含有庆大霉素和冰片的组合物及其应用
US20200352912A1 (en) Antimicrobial compositions and methods of using the same
CN118846083B (zh) 后生元和绿原酸联用组合物及其应用
Amin Current techniques and future directions in antibiotic resistance breakers
Zhang et al. Inhibitory effect of paeoniflorin on the LuxS/AI-2 quorum sensing system and the virulence of Glaesserella parasuis
Dwivedi et al. Determination of MDR mechanisms of P. aeruginosa clinical isolates
CHAUDHARY et al. Preservative evaluation of caprylic acid derivatives in aluminium hydroxide gel–USP
US20050107474A1 (en) Pharmaceutical compositions for the treatment of infections of the respiratory system by pathogenic agents
RU2618433C2 (ru) Антимикробная комбинация в отношении устойчивых к карбапенемам грамотрицательных бактерий вида pseudomonas aeruginosa, продуцирующих металло-β-лактамазу
Janus et al. Antibiotic adjuvants as a novel strategy to tackle antibiotic resistance
RU2664434C2 (ru) АНТИМИКРОБНАЯ КОМБИНАЦИЯ В ОТНОШЕНИИ УСТОЙЧИВЫХ К КАРБАПЕНЕМАМ ГРАМОТРИЦАТЕЛЬНЫХ БАКТЕРИЙ ВИДА KLEBSIELLA PNEUMONIAE, ПРОДУЦИРУЮЩИХ МЕТАЛЛО-β-ЛАКТАМАЗУ

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20141007

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180306

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190614

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20191007

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20190614

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I